Article Text

Download PDFPDF

P04.09 Development of a dendritic cell vaccine against hepatocellular carcinoma using VSV-NDV
  1. J Gold1,
  2. L Hanesch1,
  3. T Krabbe1,
  4. C Lozano-Simon1,
  5. G Hänel2,
  6. M Rothe2,
  7. A Klopp3,
  8. S Göttert4,
  9. S Heidegger4,
  10. U Protzer3,
  11. M Subklewe2 and
  12. J Altomonte1
  1. 1Department of Internal Medicine II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
  2. 2Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
  3. 3Institute of Virology at the Technical University of Munich, Munich, Germany
  4. 4Department of Internal Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany


Background Activated Dendritic cells (DC ) are the immune system’s allrounder: they initiate innate and adaptive immune responses; they induce instant immune reactions as well as immunologic memory. Therefore, there is growing interest in using them as a potential anticancer vaccine.1 Here we use the beneficial immune-stimulatory properties of the novel oncolytic hybrid virus VSV-NDV to create a DC vaccine against hepatocellular carcinoma.2

In our therapeutic approach, a sample of the patient’s tumor cells is lysed in vitro with VSV-NDV (=oncolysate). The patient’s DCs are then co-cultured in vitro with the oncolysate in order to activate them and load them with tumor antigens. In the end, the stimulated DCs are injected into the patient, where they can lead to a personalized and broad antitumor immune response.

Materials and Methods To investigate the potential of the approach in a cell culture system, human monocyte-derived dendritic cells were generated from PBMCs of healthy donors and incubated with VSV-NDV-lysed HepG2 hepatoma cells. Afterwards their state of activation was investigated via flow cytometry and cytokine measurement, whereas their functionality was assessed in co-culture with T-cells. In a murine system, dendritic cells were generated from bone marrow stem cells, incubated with a VSV-NDV-lysed murine HCC clone and investigated as in the human system.

Results Flow cytometry of oncolysate-stimulated DCs showed a significant upregulation of the activation markers CD86, MHC-I, MHC-II and PD-L1 (p < 0.05). Moreover, these stimulated DCs released increased amounts of cytokines. Upon co-culture of the DCs with T-cells, an elevated secretion of IFNγ by the T-cells, as well as an upregulation of T-cell activation markers could be shown, demonstrating the functional potential of the oncolysate-stimulated DCs. These results apply to both the human and the murine system.

Conclusions Our in vitro data demonstrates that the oncolysate-stimulated human and murine DCs are not only activated, but furthermore have a high functional potential. Further in vitro-experiments will be necessary to translate the process to patient-derived samples, whereas murine in vivo-experiments will give further insights into the effect of the therapeutic approach.


  1. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schluter M, Neitz J, Subklewe M. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. Front Immunol 2018.

  2. Abdullahi S, Jäkel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, Altomonte J. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. J Virol 2018.

Disclosure Information J. Gold: None. L. Hanesch: None. T. Krabbe: None. C. Lozano-Simon: None. G. Hänel: None. M. Rothe: None. A. Klopp: None. S. Göttert: None. S. Heidegger: None. U. Protzer: None. M. Subklewe: None. J. Altomonte: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.